Jun 25, 2008 - SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced the initiation by Merck & Co., Inc. of a Phase IIb clinical trial to evaluate the safety and efficacy of SurModics' I-vation(TM) TA in patients with diabetic macular edema.
Showing posts with label SurModics. Show all posts
Showing posts with label SurModics. Show all posts
Friday, June 27, 2008
SurModics : Initiation by Merck & Co., Inc. of Phase IIb Clinical Trial for I-vation TA
Jun 25, 2008 - SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced the initiation by Merck & Co., Inc. of a Phase IIb clinical trial to evaluate the safety and efficacy of SurModics' I-vation(TM) TA in patients with diabetic macular edema.
Subscribe to:
Posts (Atom)